2021 Corporate Governance Trends — U.S. Biopharmaceutical Industry

Sullivan & Cromwell LLP - June 2021
Download

 

Summary

 
Corporate governance issues are of critical importance to large investors evaluating investment opportunities. Mega-cap companies in the biopharmaceutical space (>$75B market cap) have aligned their governance structures to best practices across the S&P 500. Although not far behind mega-cap peers in many respects, large-cap biopharmaceutical companies ($10B to $45B market cap) have occasionally lagged in adopting those trends.

Every biopharmaceutical company should adopt a governance model that aligns with its particular characteristics, including its scientific prospects, board composition, investor base, innovation platform, commercialization program and long-term strategic objectives. Although broader industry trends are informative, companies should only evolve and develop their governance practices after engaging in deliberate conversations with directors, investors and other key stakeholders.

Click here to read more.